A lesser-known cannabinoid known as CBG has surprised scientists after a first-ever human clinical trial found that it appears to improve memory, while also “significantly” reducing anxiety and stress.
The non-intoxicating cannabinoid might not be as well-known as THC and CBD, for example, but as it’s grown in popularity, researchers at Washington State University (WSU) and the University of California at Los Angeles (UCLA) set out to investigate its therapeutic potential amid anecdotal, survey-based reports about its therapeutic potential.
The study, published in the journal Scientific Reports this month, found that cannabigerol, or CBG, caused a “significant overall reductions in anxiety as well as reductions in stress” among study participants compared to the placebo. “CBG also enhanced verbal memory relative to placebo,” with “no evidence of subjective drug effects or impairment.”
That finding about CBG’s effects on memory took the research team by surprise. Lead author and WSU associate professor of psychology Carrie Cuttler said in a press release that they “triple-checked to ensure accuracy, and the enhancement was statistically significant.”